Damora Therapeutics CEO Jennifer Jarrett acquires $252,875 of common shares
DMRA•CEO Jennifer Jarrett bought 12,500 Damora Therapeutics ordinary shares at a weighted average price of $20.23, raising her directly held stake to 512,500 shares.
1. Open-market purchase
Damora Therapeutics director, President and CEO Jennifer Jarrett bought 12,500 ordinary shares in open-market purchases. The shares were acquired at a weighted average price of $20.23, bringing her directly held stake to 512,500 ordinary shares.
